Epitope spreading possibly from BP230 to the NC16A domain of BP180 preceding disease progression in bullous pemphigoid
Abstract
1 Bonifaz A, Ram ırez-Tamayo T, Sa ul A. Tinea barbae (tinea sycosis): experience with nine cases. J Dermatol 2003; 30: 898–903. 2 Kawada A, Aragane Y, Maeda A et al. Tinea barbae due to Trichophyton rubrum with possible involvement of autoinoculation. Br J Dermatol 2000; 142: 1064–1065. 3 Watanabe S, Tsubouchi I, Okubo A. Efficacy and safety fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study. J Dermatol 2018; 45: 1151–1159. 4 Yamaguchi H. Potential of ravuconazole and its prodrugs as the new oral therapeutics for onychomycosis.Med Mycol J 2016; 57: E93–E110
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.